Onkologie. 2023:17(1):12-15 | DOI: 10.36290/xon.2023.004

Perspectives in the treatment of less common mutations in patients with non-small cell lung carcinoma

Miloš Pešek

Klinika pneumologie a ftizeologie, Fakultní nemocnice Plzeň

The author presents an overview of current information regarding the state-of-the-art in diagnosing less common driver mutations in non-small cell lung carcinoma (NSCLC) in association with the current options of treatment targeted at these molecular subtypes of cancer. In the majority of patients, targeted therapy elicits a rapid treatment response, prolongs the time to tumour progression, extends overall survival of patients, and usually has fewer adverse effects than chemotherapy in a possible combination with cancer immunotherapy. Most oncogene-dependent lung cancer occurs in non-smokers and in young individuals. NGS and RT-PCR methods are increasingly used in diagnosing these diseases, with these methods being able to demonstrate the presence of serious comutations that may affect the efficacy of targeted therapy; these tests are also used in repeated evaluation of tumour DNA in patients after failure of the original targeted therapy.

Keywords: next-generation sequencing, RT-PCR, targeted therapy, tyrosine kinase inhibitors, non-small cell lung carcinoma, comutations.

Accepted: February 22, 2023; Published: March 1, 2023  Show citation